Werewolf Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Jul 31, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 31, 2026
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
Condensed Consolidated Statements of Cash Flows (unaudited)
(amounts in thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(9,862) | $(36,071) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,348 | 3,799 |
| Depreciation expense | 2,850 | 832 |
| Loss on sale and disposal of property and equipment, net | 159 | — |
| Non-cash interest expense | 771 | 1,010 |
| Non-cash lease expense | 307 | 381 |
| Loss on extinguishment of note payable | 3,354 | — |
| Change in fair value of derivative liability | (707) | (190) |
| Gain on modification of lease liability | (1,142) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 636 | (574) |
| Accounts payable, accrued expenses and other liabilities | 1,702 | (2,348) |
| Operating lease liability | (3,384) | (951) |
| Net cash used in operating activities | (3,968) | (34,112) |
| Investing activities: | ||
| Proceeds from sale of property and equipment | 416 | — |
| Net cash provided by investing activities | 416 | — |
| Financing activities: | ||
| Repayment of note payable and extinguishment costs | (32,413) | — |
| Proceeds from at the market offering of common stock, net of issuance costs | — | 347 |
| Proceeds from issuances under Employee Stock Purchase Plan | 1 | 41 |
| Net cash (used in) provided by financing activities | (32,412) | 388 |
| Net decrease in cash, cash equivalents and restricted cash and cash equivalents | (35,964) | (33,724) |
| Cash, cash equivalents and restricted cash and cash equivalents—beginning of period | 57,951 | 112,215 |
| Cash, cash equivalents and restricted cash and cash equivalents—end of period | $21,987 | $78,491 |
| Reconciliation of cash, cash equivalents and restricted cash and cash equivalents to the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $21,987 | $77,596 |
| Restricted cash and cash equivalents | — | 895 |
| Total cash, cash equivalents and restricted cash and cash equivalents | $21,987 | $78,491 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $1,338 | $1,562 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Adjustment to right of use asset in exchange for reduction in lease liability | $4,909 | $— |
| Issuance costs in accounts payable and accrued expenses | $— | $126 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.